Related references
Note: Only part of the references are listed.Potential Survival Benefit of Secondary Cytoreductive Surgery for Recurrent Epithelial Ovarian, Tubal, and Peritoneal Cancers
Tomoko Goto et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2011)
Early versus delayed treatment of relapsed ovarian cancer
Gordon Rustin et al.
LANCET (2011)
Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study
Jean A. Hurteau et al.
GYNECOLOGIC ONCOLOGY (2010)
Ovarian cancer: relevant therapy, not timing, is paramount
Robert T. Morris et al.
LANCET (2010)
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
Gordon J. S. Rustin et al.
LANCET (2010)
Surgery in recurrent ovarian cancer:: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial
Philipp Harter et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
Share Paper
